Literature DB >> 22045598

The role of human leukocyte antigen matching in the development of multiethnic "haplobank" of induced pluripotent stem cell lines.

Pierre-Antoine Gourraud1, Leena Gilson, Mathilde Girard, Marc Peschanski.   

Abstract

Among the tools of regenerative medicine, induced pluripotent stem cells (iPSCs) are interesting because the donor genotype can be selected. The construction of banks of iPSC cell lines selected from human leukocyte antigen (HLA) homozygous donors has been proposed to be an effective way to match a maximal number of patients receiving cell therapy from iPSC lines. However, what effort would be required to constitute such a bank for a worldwide application has remained unexplored. We developed a probabilistic model to compute the number of donors to screen for constituting banks of best-chosen iPSC lines with homozygous HLA haplotypes (haplobanks) in four ancestry backgrounds. We estimated what percentage of the patients would be provided with single HLA haplotype matched cell lines. Genetic diversity leads to different outcomes for the four sets in all terms. A bank comprising iPSC lines representing the 20 most frequent haplotypes in each population would request quite different number of donors to screen, between 26,000 for European Americans and 110,000 for African Americans. It would also match different fractions of the recipient population, namely, more than 50% of the European Americans and 22% of African Americans. Conversely, a bank comprising the 100 iPSC lines with the most frequent HLA in each population would leave out only 22% of the European Americans, but 37% of the Asians, 48% of the Hispanics, and 55% of the African Americans. The constitution of a haplobank of iPSC lines is achievable through a large-scale concerted worldwide collaboration.
Copyright © 2011 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22045598     DOI: 10.1002/stem.772

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  57 in total

Review 1.  Tissue Engineering and Regenerative Medicine 2015: A Year in Review.

Authors:  Holly Wobma; Gordana Vunjak-Novakovic
Journal:  Tissue Eng Part B Rev       Date:  2016-02-23       Impact factor: 6.389

Review 2.  The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.

Authors:  Zachary S Scheiner; Sohel Talib; Ellen G Feigal
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

Review 3.  New cell sources for T cell engineering and adoptive immunotherapy.

Authors:  Maria Themeli; Isabelle Rivière; Michel Sadelain
Journal:  Cell Stem Cell       Date:  2015-04-02       Impact factor: 24.633

Review 4.  Current methods and challenges in the comprehensive characterization of human pluripotent stem cells.

Authors:  Joanna S T Asprer; Uma Lakshmipathy
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

5.  Generation of Xeno-Free, cGMP-Compliant Patient-Specific iPSCs from Skin Biopsy.

Authors:  Luke A Wiley; Kristin R Anfinson; Cathryn M Cranston; Emily E Kaalberg; Malia M Collins; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Curr Protoc Stem Cell Biol       Date:  2017-08-14

Review 6.  Immunological Issues After Stem Cell-Based β Cell Replacement.

Authors:  Valeria Sordi; Silvia Pellegrini; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

Review 7.  Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.

Authors:  Angelos Oikonomopoulos; Tomoya Kitani; Joseph C Wu
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

Review 8.  Translating induced pluripotent stem cells from bench to bedside: application to retinal diseases.

Authors:  Alona O Cramer; Robert E MacLaren
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

Review 9.  Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.

Authors:  S D Sackett; M E Brown; D M Tremmel; T Ellis; W J Burlingham; J S Odorico
Journal:  Transplant Rev (Orlando)       Date:  2016-02-10       Impact factor: 3.943

Review 10.  Embryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective.

Authors:  Qiang Bai; Romain Desprat; Bernard Klein; Jean-Marc Lemaître; John De Vos
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.